TNGX
NASDAQ · Biotechnology
Tango Therapeutics Inc
$19.48
+0.52 (+2.74%)
Financial Highlights (FY 2026)
Revenue
51.46M
Net Income
-159,365,892
Gross Margin
—
Profit Margin
-309.7%
Rev Growth
+4.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 30.1% | 30.1% |
| Operating Margin | -346.1% | -311.5% | -20.8% | -21.5% |
| Profit Margin | -309.7% | -294.2% | -27.2% | -24.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 51.46M | 49.32M | 421.41M | 456.66M |
| Gross Profit | — | — | 127.00M | 137.62M |
| Operating Income | -178,101,125 | -153,623,742 | -87,784,070 | -98,156,679 |
| Net Income | -159,365,892 | -137,463,391 | -114,600,480 | -110,156,724 |
| Gross Margin | — | — | 30.1% | 30.1% |
| Operating Margin | -346.1% | -311.5% | -20.8% | -21.5% |
| Profit Margin | -309.7% | -294.2% | -27.2% | -24.1% |
| Rev Growth | +4.3% | +4.3% | +7.1% | +20.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 721.39M | 673.97M |
| Total Equity | — | — | 1.19B | 1.15B |
| D/E Ratio | — | — | 0.61 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -165,711,671 | -150,877,982 | -127,773,532 | -138,708,079 |
| Free Cash Flow | — | — | -89,915,808 | -70,983,895 |